Downregulation of SM22α protein by hypermethylation of its promoter in colorectal cancer

Liu,Yabin; Wei,Erqiang; Zhao,Jian; Kong,Dexian; Li,Binghui

doi:10.3892/ol.2018.8350

Downregulation of SM22α protein by hypermethylation of its promoter in colorectal cancer

Authors:
- Yabin Liu
- Erqiang Wei
- Jian Zhao
- Dexian Kong
- Binghui Li
View Affiliations

Affiliations: Department of General Surgery, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Obstetrics and Gynaecology, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Endocrinology, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: March 26, 2018 https://doi.org/10.3892/ol.2018.8350
Pages: 7675-7680
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silencing of tumor suppressor genes by hypermethylation in gene promoter regions is a crucial mechanism in carcinogenesis. Gene methylation may be reversible and evaluated easily, thus providing a promising substrate for the development of biomarkers for the detection and prevention of cancer, including colorectal cancer (CRC). In the present study, the protein expression and methylation status of smooth muscle protein 22α (SM22α) was investigated in 78 cases of CRC and adjacent normal tissue. The aim of the study was to investigate the function of SM22α in the pathogenesis of CRC and to identify a candidate biomarker for the early detection of CRC. The methylation status of promoter of SM22α gene was detected using methylation‑specific polymerase chain reaction. The protein expression of SM22α was evaluated using western blot analysis. The results demonstrated a significant decrease of SM22α protein expression in 50 (68.5%) cases of CRC compared with that in adjacent normal tissues (P<0.001). The methylation status of SM22α promoter in CRC was significantly increased compared with that in adjacent normal tissues (P<0.001). Additionally, there was a negative correlation between the expression of SM22α protein and methylation levels of SM22α gene in CRC (P<0.001). Kaplan‑Meier curves revealed that patients with CRC with an unmethylated promoter of SM22α gene exhibited an increased survival time (34.8±0.6 vs. 30.9±1.3 months; P=0.025) compared with that in patients with a methylated promoter of SM22α gene. The present study demonstrated that the protein expression of SM22α is downregulated in CRC tissues by hypermethylation of its promoter, and that the methylation of SM22 α promoter may be used as a biomarker for early detection, prognosis and prediction of CRC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS and Church TR: Long-term mortality after screening for colorectal cancer. N Engl J Med. 369:1106–1114. 2013. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
4	Migliore L, Igheli F, Spisni R and Coppede F: Genetics, Cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotech. 2011:7923622011. View Article : Google Scholar
5	Grady WM and Ulrich CM: DNA alkylation and DNA methylation: Cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut. 56:318–320. 2007. View Article : Google Scholar : PubMed/NCBI
6	Inbar-Feigenberg M, Choufani S, Butcher DT, Roifman M and Weksberg R: Basic concepts of epigenetics. Fertil Steril. 99:607–615. 2013. View Article : Google Scholar : PubMed/NCBI
7	Esteller M: Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 16 Spec No. 1:R50–R59. 2007. View Article : Google Scholar
8	Fakhr Ghavifekr M, Hagh Farshdousti M, Shanehbandi D and Baradaran B: DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int. 2013:3175692013.PubMed/NCBI
9	Jaenisch R and Bird A: Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet. 33 Suppl:S245–S254. 2003. View Article : Google Scholar
10	Carmona FJ, Azuara D, Berenguer-Llergo A, Fernández AF, Biondo S, de Oca J, Rodriguez-Moranta F, Salazar R, Villanueva A, Fraga MF, et al: DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila). 6:656–665. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK and Issa JP: DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 117:1847–1854. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, Strobeck M, Yu Q and Parmacek MS: Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol. 21:1336–1344. 2001. View Article : Google Scholar : PubMed/NCBI
13	Assinder SJ, Stanton JA and Prasad PD: Transgelin: An actin-binding protein and tumour suppressor. Int J Biochem Cell Biol. 41:482–486. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lawson D, Harrison M and Shapland C: Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton. 38:250–257. 1997. View Article : Google Scholar : PubMed/NCBI
15	Shields JM, Rogers-Graham K and Der CJ: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem. 277:9790–9799. 2002. View Article : Google Scholar : PubMed/NCBI
16	Albiges-Rizo C, Destaing O, Fourcade B, Planus E and Block MR: Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J Cell Sci. 122:3037–3049. 2009. View Article : Google Scholar : PubMed/NCBI
17	Li LS and Kim H, Rhee H, Kim SH, Shin DH, Chung KY, Park KS, Paik YK, Chang J and Kim H: Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics. 4:3394–3400. 2004. View Article : Google Scholar : PubMed/NCBI
18	Prasad PD, Stanton JA and Assinder SJ: Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer. Cell Tissue Res. 339:337–347. 2010. View Article : Google Scholar : PubMed/NCBI
19	Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K and Adolf GR: Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics. 1:890–898. 2001. View Article : Google Scholar : PubMed/NCBI
20	Sayar N, Karahan G, Konu O, Bozkurt B, Bozdogan O and Yulug IG: Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer. Clin Epigenetics. 7:1042015. View Article : Google Scholar : PubMed/NCBI
21	Zhang ZW, Yang ZM, Zheng YC and Chen ZD: Transgelin induces apoptosis of human prostate LNCaP cells through its interaction with p53. Asian J Androl. 12:186–195. 2010. View Article : Google Scholar : PubMed/NCBI
22	Nair RR, Solway J and Boyd DD: Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem. 281:26424–26436. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xie XL, Liu YB, Liu YP, Du BL, Li Y, Han M and Li BH: Reduced expression of SM22 is correlated with low autophagy activity in human colorectal cancer. Pathol Res Pract. 209:237–243. 2013. View Article : Google Scholar : PubMed/NCBI
24	Gimona M, Kaverina I, Resch GP, Vignal E and Burgstaller G: Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells. Mol Biol Cell. 14:2482–2491. 2003. View Article : Google Scholar : PubMed/NCBI
25	Han M, Dong LH, Zheng B, Shi JH, Wen JK and Cheng Y: Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling. Life Sci. 84:394–401. 2009. View Article : Google Scholar : PubMed/NCBI
26	Li Q, Shi R, Wang Y and Niu X: TAGLN suppresses proliferation and invasion, and induces apoptosis of colorectal carcinoma cells. Tumour Biol. 34:505–513. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu L, Gao Y, Chen Y, Xiao Y, He Q, Qiu H and Ge W: Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer. Oncotarget. 7:43868–43893. 2016.PubMed/NCBI
28	Yu B, Chen X, Li J, Qu Y, Su L, Peng Y, Huang J, Yan J, Yu Y, Gu Q, et al: Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol. 14:172013. View Article : Google Scholar : PubMed/NCBI
29	Chen JY, Xu L, Fang WM, Han JY, Wang K and Zhu KS: Identification of PA28β as a potential novel biomarker in human esophageal squamous cell carcinoma. Tumour Biol. 39:10104283177197802017. View Article : Google Scholar : PubMed/NCBI
30	Zhao L, Wang H, Deng YJ, Wang S, Liu C, Jin H and Ding YQ: Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol. 22:786–796. 2009. View Article : Google Scholar : PubMed/NCBI
31	Yeo M, Park HJ, Kim DK, Kim YB, Cheong JY, Lee KJ and Cho SW: Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer. 116:2581–2589. 2010.PubMed/NCBI
32	Zhou HM, Fang YY, Weinberger PM, Ding LL, Cowell JK, Hudson FZ, Ren M, Lee JR, Chen QK, Su H, et al: Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell Motility. BMC Cancer. 16:552016. View Article : Google Scholar : PubMed/NCBI
33	Lin Y, Buckhaults PJ, Lee JR, Xiong H, Farrell C, Podolsky RH, Schade RR and Dynan WS: Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia. 11:864–873. 2009. View Article : Google Scholar : PubMed/NCBI
34	Prinjha RK, Shapland CE, Hsuan JJ, Totty NF, Mason IJ and Lawson D: Cloning and sequencing of cDNAs encoding the actin cross-linking protein transgelin defines a new family of actin-associated proteins. Cell Motil Cytoskeleton. 28:243–255. 1994. View Article : Google Scholar : PubMed/NCBI
35	Yamamura H, Masuda H, Ikeda W, Tokuyama T, Takagi M, Shibata N, Tatsuta M and Takahashi K: Structure and expression of the human SM22alpha gene, assignment of the gene to chromosome 11, and repression of the promoter activity by cytosine DNA methylation. J Biochem. 122:157–167. 1997. View Article : Google Scholar : PubMed/NCBI
36	Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M and Schübeler D: Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell. 30:755–766. 2008. View Article : Google Scholar : PubMed/NCBI